| scholarly article | Q13442814 |
| P356 | DOI | 10.2337/DC08-0688 |
| P932 | PMC publication ID | 2551644 |
| P698 | PubMed publication ID | 18599528 |
| P5875 | ResearchGate publication ID | 5252942 |
| P4011 | Semantic Scholar paper ID | 74e2197e3a5b0cf671f8d0e8f3d7e0e2f13bd133 |
| P50 | author | Tobias Kurth | Q39373166 |
| Giancarlo Logroscino | Q64855267 | ||
| Jane Ann Driver | Q67224418 | ||
| Ashley M Smith | Q67224419 | ||
| Julie E. Buring | Q67224421 | ||
| J. Michael Gaziano | Q67224422 | ||
| P2860 | cites work | Final report on the aspirin component of the ongoing Physicians' Health Study | Q29619461 |
| Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? | Q33733822 | ||
| Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease | Q36667311 | ||
| The relationship between diabetes mellitus and Parkinson's disease | Q40701172 | ||
| Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease | Q48216036 | ||
| Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study | Q48598689 | ||
| Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. | Q51827479 | ||
| Type 2 diabetes and the risk of Parkinson's disease. | Q53016612 | ||
| Glucose intolerance in Parkinson's disease | Q64868292 | ||
| The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism | Q78786045 | ||
| Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study | Q81087800 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| Parkinson's disease | Q11085 | ||
| P304 | page(s) | 2003-2005 | |
| P577 | publication date | 2008-07-03 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease | |
| P478 | volume | 31 |
| Q43089180 | A diet for dopaminergic neurons? |
| Q52373049 | Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease. |
| Q37212345 | Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase |
| Q92220413 | Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson's Disease: A Systematic Review |
| Q38707675 | Association between Parkinson's disease and diabetes: Data from NEDICES study |
| Q47137783 | Biological and Clinical Implications of Comorbidities in Parkinson's Disease |
| Q35677372 | Body Mass Index and Risk of Parkinson's Disease: A Dose-Response Meta-Analysis of Prospective Studies |
| Q38075505 | Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders. |
| Q47835103 | Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums |
| Q64110528 | Cardiovascular risk factors and Parkinson's disease in 500,000 Chinese adults |
| Q60938765 | Could α-Synuclein Modulation of Insulin and Dopamine Identify a Novel Link Between Parkinson's Disease and Diabetes as Well as Potential Therapies? |
| Q83440839 | Current literature in diabetes |
| Q58266631 | Determination of Endogenous Neurotoxin 1-Acetyl-6,7-Dihydroxyl-1,2,3,4-Tetrahydroisoquinoline in Rat Substantia Nigra by High Performance Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry |
| Q34718429 | Diabetes and risk of Parkinson's disease |
| Q26849796 | Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis |
| Q28538916 | Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies |
| Q35043736 | Diabetes and the risk of developing Parkinson's disease in Denmark. |
| Q37765503 | Diabetes type II: a risk factor for depression-Parkinson-Alzheimer? |
| Q91583464 | Diabetes, a Contemporary Risk for Parkinson's Disease: Epidemiological and Cellular Evidences |
| Q48677086 | Diet-induced obesity accelerates the onset of terminal phenotypes in α-synuclein transgenic mice |
| Q59813447 | Divergent Effects of Metformin on an Inflammatory Model of Parkinson's Disease |
| Q35464909 | Dopamine modulates insulin release and is involved in the survival of rat pancreatic beta cells |
| Q36367159 | Dopamine synthesis and D3 receptor activation in pancreatic β-cells regulates insulin secretion and intracellular [Ca(2+)] oscillations |
| Q37053839 | Drivers: A Biologically Contextualized, Cross-Inferential View of the Epidemiology of Neurodegenerative Disorders |
| Q33793017 | Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study |
| Q38194069 | Extra-pancreatic effects of incretin-based therapies |
| Q24596763 | Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease |
| Q38762228 | Glycation in Parkinson's disease and Alzheimer's disease |
| Q64906306 | Insulin and Autophagy in Neurodegeneration. |
| Q43067880 | KATP channel blockade protects midbrain dopamine neurons by repressing a glia-to-neuron signaling cascade that ultimately disrupts mitochondrial calcium homeostasis |
| Q55226753 | Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson’s Disease. |
| Q22252878 | Major nutritional issues in the management of Parkinson's disease |
| Q37615797 | Meta-analysis: overweight, obesity, and Parkinson's disease. |
| Q37624100 | Metabolic abnormalities and hypoleptinemia in α-synuclein A53T mutant mice. |
| Q28553200 | Metformin Prevents Nigrostriatal Dopamine Degeneration Independent of AMPK Activation in Dopamine Neurons |
| Q37050350 | Minireview: Dopaminergic regulation of insulin secretion from the pancreatic islet |
| Q37992259 | Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide |
| Q64240263 | Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways |
| Q36769272 | Obesity, diabetes, and risk of Parkinson's disease |
| Q90256243 | Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease |
| Q38994712 | Relationship Between Obesity, Alzheimer's Disease, and Parkinson's Disease: an Astrocentric View |
| Q43134736 | Reply to: Diabetes and risk of Parkinson's disease |
| Q36891855 | Risk of Parkinson Disease in Diabetes Mellitus: An Updated Meta-Analysis of Population-Based Cohort Studies |
| Q35898211 | Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. |
| Q39546196 | Statin therapy prevents the onset of Parkinson disease in patients with diabetes. |
| Q38268535 | Synopsis on the linkage of Alzheimer's and Parkinson's disease with chronic diseases. |
| Q52642685 | Targeted deletion of the aquaglyceroporin AQP9 is protective in a mouse model of Parkinson's disease. |
| Q37962621 | Targeting metabolic inflammation in Parkinson's disease: implications for prospective therapeutic strategies |
| Q57175337 | The Therapeutic Potential of Metformin in Neurodegenerative Diseases |
| Q43693957 | The association between chronic obstructive pulmonary disease and Parkinson's disease: a nationwide population-based retrospective cohort study |
| Q38914196 | The best medicine? The influence of physical activity and inactivity on Parkinson's disease |
| Q30244421 | The epidemiology of Parkinson's disease: risk factors and prevention |
| Q38174279 | The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems |
| Q28118734 | UCHL1 deficiency exacerbates human islet amyloid polypeptide toxicity in β-cells: evidence of interplay between the ubiquitin/proteasome system and autophagy |
| Q34228778 | Ubiquitin C-terminal hydrolase L1 is required for pancreatic beta cell survival and function in lipotoxic conditions |
| Q64785443 | Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial |
Search more.